2-Pyridinecarbonitrile, 5-[5-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-3-(trifluoromethyl)- manufacturers
- JNJ-pan-AR
-
- $1520.00
-
2026-05-11
- CAS:1332390-06-3
- Purity:
- Supply Ability: 10g
|
| | 2-Pyridinecarbonitrile, 5-[5-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-3-(trifluoromethyl)- Basic information |
| | 2-Pyridinecarbonitrile, 5-[5-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-3-(trifluoromethyl)- Chemical Properties |
| Boiling point | 657.0±65.0 °C(Predicted) | | density | 1.47±0.1 g/cm3(Predicted) | | pka | 8.16±0.10(Predicted) |
| | 2-Pyridinecarbonitrile, 5-[5-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-3-(trifluoromethyl)- Usage And Synthesis |
| Description | JNJ-pan-AR, a meylated analogue of JNJ-63576253, is a novel pan-AR antagonist with potent activity against wild-type and clinically relevant AR mutations including F877L. JNJ63576253, also known as TRC253, is a potent and orally active androgen receptor antagonist. TRC253 specifically binds to both wild-type and certain mutant forms of AR, thereby preventing androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. |
| | 2-Pyridinecarbonitrile, 5-[5-[4-[(1-methyl-4-piperidinyl)oxy]phenyl]-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-7-yl]-3-(trifluoromethyl)- Preparation Products And Raw materials |
|